Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 128.497 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 32.124 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 64.249 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; povidone; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Canada - English - Health Canada

dr reddy's laboratories ltd - sitagliptin (sitagliptin phosphate); metformin hydrochloride - tablet - 50mg; 500mg - sitagliptin (sitagliptin phosphate) 50mg; metformin hydrochloride 500mg

Canada - English - Health Canada

dr reddy's laboratories ltd - sitagliptin (sitagliptin phosphate); metformin hydrochloride - tablet - 50mg; 850mg - sitagliptin (sitagliptin phosphate) 50mg; metformin hydrochloride 850mg

Canada - English - Health Canada

dr reddy's laboratories ltd - sitagliptin (sitagliptin phosphate); metformin hydrochloride - tablet - 50mg; 1000mg - sitagliptin (sitagliptin phosphate) 50mg; metformin hydrochloride 1000mg

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - sitagliptin phosphate monohydrate 128.5mg equivalent to 100 mg sitagliptin - film coated tablet - 100 mg - active: sitagliptin phosphate monohydrate 128.5mg equivalent to 100 mg sitagliptin excipient: calcium hydrogen phosphate croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate   microcrystalline cellulose purified talc titanium dioxide - monotherapy: sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. combination with metformin: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when diet and exercise, plus the single agent do not provide adequate glycaemic control. combination with a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a ppar-gamma agonist (i.e. thiazolidinediones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a ppar-gamma agonist (i.e. thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with insulin: sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin (with or without metformin).

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - sitagliptin phosphate monohydrate 32.125mg equivalent to 25 mg sitagliptin - film coated tablet - 25 mg - active: sitagliptin phosphate monohydrate 32.125mg equivalent to 25 mg sitagliptin excipient: calcium hydrogen phosphate croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate   microcrystalline cellulose purified talc titanium dioxide - monotherapy: sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. combination with metformin: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when diet and exercise, plus the single agent do not provide adequate glycaemic control. combination with a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a ppar-gamma agonist (i.e. thiazolidinediones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a ppar-gamma agonist (i.e. thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with insulin: sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin (with or without metformin).

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - sitagliptin phosphate monohydrate 64.25mg equivalent to 50 mg sitagliptin - film coated tablet - 50 mg - active: sitagliptin phosphate monohydrate 64.25mg equivalent to 50 mg sitagliptin excipient: calcium hydrogen phosphate croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate   microcrystalline cellulose purified talc titanium dioxide - monotherapy: sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. combination with metformin: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when diet and exercise, plus the single agent do not provide adequate glycaemic control. combination with a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a ppar-gamma agonist (i.e. thiazolidinediones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a ppar-gamma agonist (i.e. thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with insulin: sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin (with or without metformin).